# George Rehm

> George Rehm is a Series D investor at Aeris Capital backing Health Care and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aeris Capital](https://shizune.co/investors/profile/aeris-capital)
- Location: Frankfurt, Germany
- Total investments: 10
- Last investment: Jun 2016
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://de.linkedin.com/in/george-rehm-78182

George Rehm is a Series D investor at Aeris Capital in Frankfurt focused on Health Care and Biotechnology. George Rehm is the Board Member at Tethys Bioscience.George Rehm is a managing partner of aeris CAPITAL AG in Switzerland and has over twenty-five years experience as a lawyer and executive in international licensing, technology transfer and investment and privatization transactions in the US, Europe and Asia. Along with his current careerin private equity, he also holds board seats in,ViaLogy PLC, Barnev Inc., Sensovation AG,TTTech AG. In his capacity as Board member, George has been actively involved in international licensing transactions, IP strategy and product licensing transactions, as well as leading a major transatlantic financing round. Prior to beginning his career in private equity with aeris in 2000, George functioned as legal counsel for numerous international technology transfer transactions, including deals in China and Russia for Applied Materials, Monsanto, Dow Corning and Mitsubishi Heavy Metals. He was a member of a law practice focusing on privatization and cross-border investment transactions in Eastern Germany, the Czech Republic and the former USSR for over eight years. He also served as legislative counsel on foreign trade and European Investment to major US electronics industry associations (AEA, SEMI), providing testimony and representation to them before the US Congress. George was also active as chief European consultant to Bristol-Myers-Squibb on an oncology care project, involving delivery of services through ambulatory clinics throughout the EU. He has served as CEO of a European health care IT developer, which he successfully sold to Data Card Corporation, and was instrumental in guiding a German incubator through successful Series A financing by a major German family foundation. George remains as counsel in the Munich, Heidelberg and Berlin law firm Weitnauer Partners. He received his BSFS from Georgetown University. He received his J.D. from the University of California, Hastings College of Law. George has written and lectured frequently in Germany and the US on international trade, investment, technology transfer, health care, and venture capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 50% |
| Biotechnology | 4 | 40% |
| Medical | 3 | 30% |
| Mobile | 1 | 10% |
| Genetics | 1 | 10% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 3 | 30% |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Series C | 2 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 40% |
| Canada | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $17.7M | Series C | Jun 07, 2016 |  |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $23.3M | Series C | May 21, 2015 |  |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $18.3M | Series B | Sep 23, 2014 |  |
| GenomeDx Biosciences | GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine. |  | Series B | Sep 30, 2013 |  |
| Crescendo Bioscience | Crescendo Bioscience, Inc. develops quantitative and objective diagnostic tools to provide rheumatologists with clinical insights to manage patients with autoimmune and inflammatory diseases. It provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians. Crescendo Bioscience, Inc. was formerly known asRiley Genomics, Inc. The company was founded in 2002 and is based in South San Francisco, California. | $28M | Series D | Jan 03, 2013 |  |
| Jiff | Jiff is a venture-backed, Mountain View-based technology company that is reinventing healthcare, one employee at a time. It builds customized mobile and web experiences that connect company benefits and incentives design to healthy employee behaviors using the wearables and apps that they all know and love.The company was founded in 2010 and isheadquartered in Mountain View, California. | $7.5M | Series A | Mar 12, 2012 |  |
| Crescendo Bioscience | Crescendo Bioscience, Inc. develops quantitative and objective diagnostic tools to provide rheumatologists with clinical insights to manage patients with autoimmune and inflammatory diseases. It provides diagnostic, prognostic, staging, therapy selection, and monitoring facilities to physicians. Crescendo Bioscience, Inc. was formerly known asRiley Genomics, Inc. The company was founded in 2002 and is based in South San Francisco, California. | $31M | Series C | Sep 08, 2011 |  |
| Tethys BioScience | Tethys BioScience, Inc. engages in the discovery, development, and commercialization of biological markers. Its products are used to diagnosis the metabolic diseases, such as diabetes. The company offers PreDx Diabetes Risk Test, a diagnostic test that analyzes a set of multiple proteins and other blood borne biomarkers implicated in thedevelopment of diabetes. Tethys BioScience, Inc. was founded in 2002 and is based in Emeryville, California. | $25M | Series D | Nov 09, 2009 |  |
| Adamas Pharmaceuticals | Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. Thecompany was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore. | $40M | Series D | Oct 01, 2009 |  |
| BioPheresis | BioPheresis Technologies is a US Delaware corporation, and its wholly owned operating company, BioPheresis GmbH, incorporated in 2003, is located in Heidelberg, Germany. BioPheresis has developed a new patent protected blood treatment system designed to remove specific cancer-protecting immune-inhibitors from the blood. | $8M | Series A | May 13, 2005 |  |

10 of 10 investments shown.

## Co-investors
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 3 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 3 deals together
- [Mohr Davidow Ventures](https://shizune.co/investors/profile/mohr-davidow-ventures) — VC Fund, 3 deals together
- [Ooga Labs](https://shizune.co/investors/profile/ooga-labs) — VC Fund, 2 deals together
- [Baird Capital](https://shizune.co/investors/profile/baird-capital) — VC Fund, 1 deal together
- [GE Ventures](https://shizune.co/investors/profile/ge-ventures) — VC Fund, 1 deal together

## About Aeris Capital

VC Fund · Pfaffikon, Switzerland

Aeris Capital AG is a private equity fund and financial advisor with locations in the United States and Switzerland.

1 contacts available at Aeris Capital.

| Name | Title | Profile |
| --- | --- | --- |
| George Rehm | Managing Director | https://shizune.co/investors/profile/george-rehm |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does George Rehm invest in?

George Rehm invests primarily in Health Care, Biotechnology and Medical startups, most often at Series D and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did George Rehm last invest?

The most recent investment recorded for George Rehm closed in Jun 2016. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co